![Richard Taylor](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard Taylor
Direttore/Membro del Consiglio presso Celleron Therapeutics Ltd.
Posizioni attive di Richard Taylor
Società | Posizione | Inizio | Fine |
---|---|---|---|
Celleron Therapeutics Ltd.
![]() Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Richard Taylor
Statistiche
Distribuzione geografica
Regno Unito | 2 |
Posizioni
Director/Board Member | 1 |
Settori
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Celleron Therapeutics Ltd.
![]() Celleron Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue. | Health Technology |
- Borsa valori
- Insiders
- Richard Taylor
- Esperienza